| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_14effe3850d2129f863b969dac4f1db8 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y10S530-825
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-235
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-099
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12P1-00 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-295
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-102
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-235
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-116 |
| filingDate |
1995-05-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
1999-03-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fa092e2bd55fee99489e93e4906e7859
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a5e5a385d1e762ae43424ee77907bee3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a28a5e24614df8462b66c4dadb66c290
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1f061df502c53724a1379d489cac561c |
| publicationDate |
1999-03-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-5885587-A |
| titleOfInvention |
Efficacious vaccines against Bordetella pertussis comprising a combination of individually purified pertussis antigens |
| abstract |
This invention is directed to a vaccine for the prevention of disease caused by Bordetella pertussis which comprises the pertussis antigens filamentous hemagglutinin, detoxified lymphocytosis promoting factor and a 69 kilodalton outer membrane protein, where said antigens are individually purified prior to being combined to form the vaccine. The invention is further directed to pertussis vaccines where the antigens are combined in any ratio, including ratios not possible in whole cell or co-purified acellular pertussis vaccines. The pertussis antigens may be further combined with other individually purified pertussis antigens, pertussis structural components, adjuvants, stabilizers and non-pertussis vaccine components. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2002009466-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2005032584-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2005032584-A3
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6444211-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7087236-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2007116711-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7479283-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6524946-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6210685-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2008254134-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8574596-B2 |
| priorityDate |
1990-07-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |